186 related articles for article (PubMed ID: 30509113)
1. Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review.
Sanguedolce F; Russo D; Mancini V; Selvaggio O; Calò B; Carrieri G; Cormio L
Int J Surg Pathol; 2019 Apr; 27(2):120-133. PubMed ID: 30509113
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
Cox RM; Magi-Galluzzi C; McKenney JK
Adv Anat Pathol; 2018 Nov; 25(6):387-399. PubMed ID: 30157041
[TBL] [Abstract][Full Text] [Related]
3. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract][Full Text] [Related]
4. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia.
Hodges KB; Lopez-Beltran A; Emerson RE; Montironi R; Cheng L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):401-10. PubMed ID: 20505509
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical stains to detect residual tumor in cystectomy specimens taken shortly after transurethral resection of bladder tumors.
Barresi V; Nunnari CM; Lionti S
Ann Diagn Pathol; 2019 Jun; 40():176-179. PubMed ID: 30266536
[No Abstract] [Full Text] [Related]
8. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
9. Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.
Arista-Nasr J; Martinez-Benitez B; Bornstein-Quevedo L; Aguilar-Ayala E; Aleman-Sanchez CN; Ortiz-Bautista R
Int Braz J Urol; 2016; 42(2):247-52. PubMed ID: 27256178
[TBL] [Abstract][Full Text] [Related]
10. Urothelial Carcinoma With Villoglandular Differentiation: A Rare Entity.
Mitra S; Sundaram AK; Gupta K; Devana SK
Int J Surg Pathol; 2016 Jun; 24(4):356-9. PubMed ID: 26721305
[TBL] [Abstract][Full Text] [Related]
11. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms.
McKenney JK; Amin MB
Semin Diagn Pathol; 2005 Feb; 22(1):69-87. PubMed ID: 16512600
[TBL] [Abstract][Full Text] [Related]
12. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.
Varinot J; Cussenot O; Roupret M; Conort P; Bitker MO; Chartier-Kastler E; Cheng L; Compérat E
Virchows Arch; 2013 Dec; 463(6):803-9. PubMed ID: 24146108
[TBL] [Abstract][Full Text] [Related]
13. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
Mazzucchelli R; Barbisan F; Santinelli A; Scarpelli M; Galosi AB; Lopez-Beltran A; Cheng L; Kirkali Z; Montironi R
Urology; 2009 Aug; 74(2):385-90. PubMed ID: 19501882
[TBL] [Abstract][Full Text] [Related]
14. Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma.
Lerner SP; Colen J; Shen S
Curr Opin Urol; 2008 Sep; 18(5):508-12. PubMed ID: 18670276
[TBL] [Abstract][Full Text] [Related]
15. High grade prostatic adenocarcinoma with a partly intraductal growth pattern producing a mimic of urothelial carcinoma in situ.
Shaw EC; Oxley JD; Varma M; Theaker J
J Clin Pathol; 2013 Aug; 66(8):729-31. PubMed ID: 23268319
[No Abstract] [Full Text] [Related]
16. Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
Bösherz MS; Samarska IV; Gaisa NT
Methods Mol Biol; 2023; 2684():3-25. PubMed ID: 37410225
[TBL] [Abstract][Full Text] [Related]
17. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
18. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
[TBL] [Abstract][Full Text] [Related]
19. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract][Full Text] [Related]
20. Problems arising in the diagnosis of primary ovarian transitional cell carcinoma after the occurrence of a transitional cell carcinoma of the bladder: a report of a difficult case and a critical review of literature.
Raspollini MR; Paglierani M; Taddei GL
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):178-83. PubMed ID: 19521281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
